CHIESI FARMACEUTICI S.P.A.
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1935-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chiesigroup.com
Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Participants Undergoing Surgery (PIONEER)
Phase 4
Terminated
- Conditions
- Pediatric Perioperative Blood Pressure Management
- Interventions
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 22
- Registration Number
- NCT01938547
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Stanford Medical Center, Stanford, California, United States
Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Beclometasone/Formoterol/Glycopyrrolate
- First Posted Date
- 2013-08-06
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 1368
- Registration Number
- NCT01917331
- Locations
- 🇭🇺
Dr Beatrix BALINT, Szeged, Hungary
Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 3686
- Registration Number
- NCT01911364
- Locations
- 🇮🇹
Azienda Ospedaliera Perugia, Perugia, Italy
🇩🇪Institut für klinische Forschung, Hessen, Germany
🇭🇺Csongrád Megyei Mellkasi Betegségek Szakkórháza, Szeged, Hungary
Lamazym Aftercare Study
- First Posted Date
- 2013-07-26
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 8
- Registration Number
- NCT01908725
- Locations
- 🇩🇰
Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, Denmark
Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients
- First Posted Date
- 2013-07-26
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 13
- Registration Number
- NCT01908712
- Locations
- 🇫🇷
Hôpital Femme Mére Enfant - CHU de Lyon, Bron, France
Clinical Pharmacology Study of CHF1535 pMDI 50/6 µg Versus The Free Combination In Asthmatic Children 5-11 Years Old
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2013-05-07
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 20
- Registration Number
- NCT01848769
- Locations
- 🇩🇰
BorneAstmaKlinikken, Copenhagen, Denmark
Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- Drug: Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1Drug: CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2).Drug: CHF 1535 100/6 pMDI (Foster®) (CTR)
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 60
- Registration Number
- NCT01803087
- Locations
- 🇵🇱
Uniwersytecki Szpital Kliniczny nr 1, Lodz, Poland
Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder
Phase 2
Completed
- Conditions
- Asthmatic
- Interventions
- Drug: NEXThaler 200/6 mcg DPIDrug: NEXThaler placeboDrug: NEXThaler 100/6 mcg DPI
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 30
- Registration Number
- NCT01738087
- Locations
- 🇬🇧
The Medicine Evaluation Unit, Manchester, United Kingdom
Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 55
- Registration Number
- NCT01730404
- Locations
- 🇮🇪
Celerion, Belfast, Ireland
🇬🇧Medicines Evaluation Unit Ltd, Manchester, United Kingdom
🇬🇧Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers (HV)
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: CHF 6001 SD or placeboDrug: CHF 6001 MD or placebo
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 74
- Registration Number
- NCT01703052
- Locations
- 🇬🇧
Quotient Clinical, Nottingham, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath